🔬 Pharmidex is proud to contribute to new research!
June 10, 2025
We’re excited to announce our involvement in the recent publication:
"Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4"
📄
https://pubmed.ncbi.nlm.nih.gov/40245851/
📄
https://www.pharmidex.com/publications-by-pharmidex
Dr.
Radhakrishnan Venkatasamy, our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential.
This reflects
Pharmidex’s commitment to advancing therapies through expert science and collaboration.
#Pharmidex #DrugDiscovery #Inflammation #Ensifentrine
Head of Respiratory at Pharmidex , Ian Knowles will be attending the Drug Delivery to the Lungs Conference (DDL) on 10–12 December 2025 at the Edinburgh International Conference Centre. DDL brings together global leaders in pulmonary and respiratory drug delivery, and Ian looks forward to meeting fellow attendees, exploring collaborations, and discussing how Pharmidex can support and accelerate drug discovery and development across industry and academia. If you’ll be there too, feel free to reach out we look forward to building new connections and advancing innovation together.
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) and Janette Dalay Robertson will attend the “Recent Clinical Candidates and SMR Award Meeting” this Thursday, 4 December 2025. If you’re attending, we’d be happy to connect!
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) , and our Dr. Ian Knowles , will attend Genesis 2025 this Wednesday, December 3rd, hosted by One Nucleus . They look forward to meeting fellow attendees, exploring new collaborations, and building partnerships with companies and academic groups to advance drug discovery and development. See you at Genesis 2025!
